/EINPresswire.com/ -- WEST KELOWNA, BC --(Marketwired - March 08, 2016) - FPS PHARMA INC. ("FPS Pharma" or the "Company") is pleased to announce that FPS Pharma Asia Limited (the "Licensee" and /or "FPS Pharma Asia"), a wholly owned Hong Kong subsidiary, has signed an exclusive Intellectual Property Rights ("IP Rights") Licensing Agreement with Florida based AfGin Pharma Licensing, LLC (the "Licensor"). 

The IP Rights mean the Licensor's rights in:

(a)  a unique drug delivery system encompassing know-how, inventions,       
     technical data and specifications, formulations, technology, trade     
     secrets, intellectual property, and other proprietary methods and      
     information involving:                                                 
                                                                            
     (i)   the topical application of medications at the back of the neck at
           the hairline ("BONATH") and elsewhere at the back of the neck,   
           back of ears, and temples, used soley or in combination with     
           other drugs commonly thought to work synergistically for the     
           treatment of migraine and other chronic headache conditions (also
           described in United States Patent No. 8,329,734 issued on        
           December 11, 2012 entitled Topical Therapy for Migraine);        
                                                                            
     (ii)  the topical application of medications at the back of the neck at
           the hairline ("BONATH") and elsewhere at the back of the neck,   
           back of ears and temples, used soley for the treatment of        
           Parkinson's disease (also as described in United States Patent   
           No. 8,592,424 issued on November 26, 2013 entitled Topical       
           Regional Neuro-Affective Therapy) or                             
                                                                            
     (iii) the topical application of medications to the peripheral nerves: 
           feet, hands, scalp, and other specific areas of peripheral       
           neuropathic dysfunction for the treatment of diabetic peripheral 
           neuropathy, chemotherapy related peripheral neuropahy, hereditary
           peripheral neuropathies, and certain other peripheral neuropathic
           processes (also as described in United States Patent Application 
           No. 61/935,553 filed February 4, 2014, entitled Topical          
           Peripheral Neuro-Affective (TPNA) Therapy for Neuropathic        
           Conditions; and                                                  
                                                                            
(b)  any related IP Rights and patent applications and patents that issue in
     the Field and Territory with respect to the aforesaid technology,      
     including without limitation all divisional, continuations, reissues,  
     renewals, re-examinations, extensions or additions to any such IP      
     Rights.                                                                

FPS Pharma Asia has the exclusive IP Rights for Indonesia, Malaysia, Thailand, Laos, Cambodia, Viet Nam, Myanmar, Sri Lanka and Hong Kong.

The Licensor's compensation is based on a running royalty rate of 5% of Net Product Sales of FPS Pharma Asia.

ON BEHALF OF THE BOARD OF DIRECTORS

"James R. Brown"

James R. Brown
Chairman, President & CEO

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release.

James R. Brown
778-754-3000

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.